Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives-Reference-Cited by-同舟云学术

Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives

Published:2020-11 Issue:4 Volume:15 Page:
ISSN:1479-6708
Container-title:Future Neurology
language:en
Short-container-title:Future Neurology

Author:

Correll Christoph U¹²³^ORCID,Demyttenaere Koen⁴^ORCID,Fagiolini Andrea⁵^ORCID,Hajak Göran⁶^ORCID,Pallanti Stefano⁷^ORCID,Racagni Giorgio⁸^ORCID,Singh Swaran⁹^ORCID

Affiliation:

1. Department of Psychiatry Research, The Zucker Hillside Hospital, 75–59 263rd Street Glen Oaks, NY 11004, USA

2. Department of Psychiatry & Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY 11549, USA

3. Department of Child & Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany

4. University Psychiatric Center KU Leuven, Campus Gasthuisberg & University of Leuven, Psychiatry Research Group, Department of Neurosciences, Faculty of Medicine, Herestraat 49, Leuven 3000, Belgium

5. Department of Molecular Medicine, University of Siena School of Medicine, Siena 53100, Italy

6. Department of Psychiatry, Psychosomatic Medicine & Psychotherapy, Sozialstiftung Bamberg, St.-Getreustrasse 18, Bamberg 96049, Germany

7. Istituto di Neuroscienze via Lamarmora 24, Firenze, Italy

8. Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Via G. Balzaretti 9, Milano 20123, Italy

9. Mental Health & Wellbeing, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK

Abstract

In schizophrenia, dopaminergic hyperactivity in the mesolimbic regions, or possibly even selectively so in the dorsal striatum, seems to cause the emergence of psychotic symptoms, whereas dopaminergic hypoactivity in cortical regions underlies the negative symptoms and cognitive deficits. Managing the negative symptoms is a major current challenge in the treatment of schizophrenia with a dearth of novel modalities to address this clinical issue. Cariprazine is a novel second-generation antipsychotic that specifically targets the D3 receptor mainly associated to negative symptoms. The review summarizes the main issues regarding negative symptom management and the role of cariprazine treatment.

Publisher

Future Medicine Ltd

Subject

Neurology (clinical),Neurology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fnl-2020-0012

Reference58 articles.

1. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment

2. Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms

3. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: A CATIE analysis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Appropriateness of Cariprazine in the Management of Schizophrenia: Experts’ Opinion using a Delphi Approach;Current Neuropharmacology;2023-11

2. Cariprazine for negative symptoms in early psychosis: a pilot study with a 6-month follow-up;Frontiers in Psychiatry;2023-06-22

3. A Novel Psychosocial Intervention for Motivational Negative Symptoms in Schizophrenia: Combined Motivational Interviewing and CBT;American Journal of Psychiatry;2023-05-01

4. Schizophrenia Synaptic Pathology and Antipsychotic Treatment in the Framework of Oxidative and Mitochondrial Dysfunction: Translational Highlights for the Clinics and Treatment;Antioxidants;2023-04-21

5. Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung;Arzneiverordnungs-Report 2023;2023